Abeona Therapeutics Posts 18% Revenue Jump for ZEVASKYN, Acquires EoE Drug Candidate and Raises $30 Million

Abeona Therapeutics reported third-quarter 2026 net ZEVASKYN revenue of $13.5 million, an 18% sequential increase from $11.4 million in the second quarter. The company's GAAP loss per share of $0.08 beat consensus estimates by $0.10, though total revenue of $13.49 million fell $1.33 million short of expectations. Abeona held $134.9 million in cash, cash equivalents, and short-term investments as of September 30, 2026.

On the commercial front, 15 ZEVASKYN treatments have been completed since the product's launch, including six during the third quarter. The qualified treatment center network expanded to eight sites, with four having completed patient treatments. ZEVASKYN also gained New Technology Add-on Payment status, which became effective October 1, 2026, a development that could support broader hospital adoption.

Separately, Abeona announced the acquisition of APT-1011, now renamed ABO-801, a Phase 3-ready once-daily oral disintegrating tablet formulation of fluticasone propionate for eosinophilic esophagitis, from Ellodi Pharmaceuticals under an Asset Purchase Agreement signed November 6, 2026. The deal required no upfront cash payment; instead, Abeona issued Ellodi $20 million worth of common stock, amounting to 4,494,383 shares, with an additional $30 million milestone payment due upon FDA approval. To fund development of the new asset, the company also entered into a securities purchase agreement for a $30 million private placement. Shares fell 12.5% in pre-market trading following the announcements.